Onkologie. 2008:2(1):44-48

GENETICS OF BREAST CARCINOMA

Lenka Foretová
Oddělení epidemiologie a genetiky nádorů, Masarykův onkologický ústav, Brno

Five to ten percent of breast carcinoma is caused by monogenic hereditary predisposition. The main predisposition genes BRCA1 and BRCA2 were discovered in 1994 and 1995. Molecular genetic testing of these genes is possible in indicated cases like bilateral or early-onset breast cancer, familiar occurrence of the disease, breast and ovarian cancer in a patient and in some rare histological types of breast cancer. Prevention in carriers of mutation should be complex and cover risks of other cancers as ovarian, colorectal, pancreatic, stomach, gall bladder, melanoma, prostate and breast in men. Predictive testing is possible in relatives 18 years and older in families with detected mutation. In a proportion of families pathogenic mutation is not detected by molecular genetic methods but monogenic inheritance is very probable. Testing of healthy relatives is not possible, but preventive surveillance is necessary in all individuals at risk. In those families germline mutations in other genes may be a cause of genetic predisposition.

Keywords: genetic testing, BRCA1 gene, BRCA2 gene, mutation, hereditary predisposition, prevention

Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Foretová L. GENETICS OF BREAST CARCINOMA. Onkologie. 2008;2(1):44-48.
Download citation

References

  1. Bartoňková H, Foretová L, Helmichová E, Kalábová R, Kleibl Z, Konopásek B, Krutílková V, Macháčková E, Novotný J, Petráková K, Petruželka L, Plevová P, Pohlreich P, Rob L, Skovajsová M, Veselý J, Žaloudík J. Doporučené zásady péče o nemocné s nádory prsu a vaječníků a zdravé osoby se zárodečnými mutace genů BRCA1 nebo BRCA2. Klinická onkologie 2003; 16 (1): 28-34.
  2. Berchuck A, Schildkraut JM, Marks JR et al. Managing hereditary ovarian cancer risk. Cancer Suplement 1999; 86: 2517-2524. Go to original source... Go to PubMed...
  3. Blanchard DK, Hartmann LC. Prophylactic surgery for women at high risk for breast cancer. Clin Breast Cancer, 2000; 1: 127-134. Go to original source... Go to PubMed...
  4. Dražan L. Profylaktická mastektomie a její indikace u rizikových žen. Klinická onkologie Suppl. 2006; 19: 97-100.
  5. Eisen A, Rebbeck TR, Wood WC et al. Prophylactic Surgery in Women With a Hereditary Predisposition to Breast and Ovarian Cancor. 2000; JCO 18, 1980-1995.
  6. Fisher B, Constantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 1999; 90: p. 1371-1388. Go to original source... Go to PubMed...
  7. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am.J.Hum.Genet. 1998; 62: 676-689. Go to original source... Go to PubMed...
  8. Foretová L, Macháčková E, Navratilova M et al. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Human Mutation 2004; 23 (4): 397-398. Go to original source... Go to PubMed...
  9. Foretová L, Navrátilová M, Petráková K, Palácová M, Kalábová R. Puchmajerová A, Novotná K, Sedláček Z. Kazuistiky Li-Fraumeni syndromu: diagnostické a preventivní možnosti. Klinická onkologie Suppl. 2006; 19: 85-87.
  10. Goetz P, Foretová L, Puchmajerová A. Hereditární etiologie nádorových onemocnění a význam genetického poradenství a testování v onkologii. Klinická onkologie Suppl, 2006; 19: 44-47.
  11. Grabick DM., Hartmann LC, Cerhan JR et al. Risk of breast cancer with oral contraceptive use in women with family history of breast cancer. JAMA 2000; 284: 1791-1798. Go to original source... Go to PubMed...
  12. Hisada M, Garber JE, Fung CY et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J. Natl. Cancer Inst. 1998; 90: 606-611. Go to original source... Go to PubMed...
  13. Hughes KS, Papa MZ, Whitney T et al. Prophylactic mastectomy and inherited predisposition to breast carcinoma. Cancer Suplement. 1999; 86: 2502-2515. Go to original source...
  14. King MC, Wieand S, Hale K. Tamoxifen use reduces breast cancer risk in BRCA2 positive women. JAMA 2001; 286: 2251-2256. Go to original source... Go to PubMed...
  15. Kleibl Z, Novotný J, Bezdíčková D, Malik R, Kleiblová P, Foretová L, Petruželka L, Ilenčiková D, Cinek P, Pohlreich P. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Res Treat. 2005; 90(2): 165-167. Go to original source... Go to PubMed...
  16. Krutílková V, Trková M, Kodet R, Sumerauer D, Nekolná M, Seemanová E, Vodvářka P, Foretová L, Goetz P, Sedláček Z. Syndrom Li-Fraumeni. Čs pediatrie 2003; 58 (9): 552-555.
  17. Lindor NM, Greene MH, The Mayo Familial Cancer Program. The Concise Handbook of Family Cancer Syndromes. J Natl Cancer Inst. 1998; 90: 1039-1071. Go to original source... Go to PubMed...
  18. Lukešová M, Macháčková E, Vašíčková P, Nvrátilová M, Pavlů H, Urbánková V, Kuklová J, Foretová L. Výsledky testování BRCA1 a BRCA2 genů v molekulárně genetické laboratoři Masarykova onkologického ústavu. Klinická onkologie Suppl. 2006; 19: 48-54.
  19. Macháčková E, Plevová P, Lukešová M, Šilhánová E, Foretová L. Genetická predispozice ke vzniku maligního nádoru prsu. Klinická onkologie Suppl. 2006; 19: 48-54.
  20. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CTM et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet. 2000; 355: 2015-2020. Go to original source... Go to PubMed...
  21. Meijers-Heijboer H, van Geel B, van Putten WLJ et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2001; 345: 159-63. Go to original source... Go to PubMed...
  22. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71. Go to original source... Go to PubMed...
  23. Modan B, Hartge P, Hirsh-Yechezkel G et al. Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a BRCA1 or BRCA2 Mutation. N Engl J Med, 2001; 345: 235-240. Go to original source... Go to PubMed...
  24. Narod SA, Risch H, Moslehi R et al. Oral Contraceptives and the Risk of Hereditary Ovarian Cancer, N Engl J Med 1998; 339: 424-428. Go to original source... Go to PubMed...
  25. Petráková K, Palácová M, Foretová L, Kalábová R. Algorytmus preventivních vyšetření u geneticky podmíněných malignit. Klinická onkologie Suppl. 2006; 19: 88-90.
  26. Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med, 2002; 346: 1616-1622. Go to original source... Go to PubMed...
  27. Rebbeck TR. Inherited genetic predisposition in breast cancer. A population-based perspective. Cancer 1999; 86: 2493-2501. Go to original source... Go to PubMed...
  28. Rebbeck TR, Levin AM, Eisen A et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J.Natl.Cancer Inst. 1999; 91: 1475-1479. Go to original source... Go to PubMed...
  29. Schneiderová M, Bartoňková H. Úloha magnetické rezonance v mammologické prevenci u žen s dědičným rizikem nádoru prsu. Klinická onkologie Suppl. 2006; 19: 91-96.
  30. Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, The Breast Cancer Linkage Consortium. Futreal AP, Nathanson KL, Weber BL, Easton DF, Stratton MR, Rahman N. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am.J.Hum.Genet. 2003; 72: 1023-1028. Go to original source... Go to PubMed...
  31. Ursin G, Henderson BE, Haile WR et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 1997; 57: 3678-3681.
  32. Varley JM, Evans DGR, Birch JM. Li-Fraumeni syndrome - a molecular and clinical review. British Journal of Cancer 1997; 76 (1): 1-14. Go to original source... Go to PubMed...
  33. Vašíčková P, Macháčková E, Lukešová M, Horký O, Pavlů H, Kuklová J, Urbánková V, Foltánková V, Navrátilová M, Foretová L. Varianty neznámého významu a intragenová přeskupení v genech BRCA1 a BRCA2. Klinická onkologie Suppl. 2006; 19: 58-62.
  34. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006; 295(12): 1379-88. Go to original source... Go to PubMed...
  35. Warner E, Plewes DB, Shumak RS. Comparison of Breast Magnetic Resonance Imaging, Mammography, and Ultrasound for Surveillance of Women at High Risk for Hereditary Breast Cancer. J Clin Oncol 2001; 19: 3524-3531. Go to original source... Go to PubMed...
  36. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature,1995; 378: 789-792. Go to original source... Go to PubMed...
  37. Zikan M, Foretova L, Cibula D, Kotlas J, Pohlreich P. Hereditary ovarian cancer - Review. Ceska Gynekol. 2006; 71(3): 246-251.
  38. Zikán M, Jančárková N, Pohlreich P, Matouš B, Kleibl Z, Stříbrná J, Živný J. Hereditární dispozice ke karcinomu prsu a ovaria. Časopis lékařů českých 2004; 143 (1): 26-30. Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.